Bioventix PLC creates, manufactures, and supplies sheep monoclonal antibodies (SMAs) for diagnostic applications worldwide. The company offers a portfolio of purified SMAs for thyroid, vitamin D, cardiac, drugs of abuse, fertility, oncology, and miscellaneous indications; and Pyrene (HOP-G) ELISA kit to monitor human exposure to industrial pollutants. It also provides contract SMAs and recombinant services. Bioventix PLC was incorporated in 2003 and is based in Farnham, the United Kingdom.
Stock data | 2023 | Change |
---|---|---|
Price | $46.04 | N/A |
Market Cap | $239.98M | N/A |
Shares Outstanding | 5.21M | 0.06% |
Employees | 12.00 | N/A |
Shareholder Equity | 12.06M | 2.05% |
Valuation | 2023 | Change |
---|---|---|
P/E Ratio | 29.09 | N/A |
P/S Ratio | 14.84 | N/A |
P/B Ratio | 19.89 | N/A |
Growth | 2023 | Change |
---|---|---|
Return on Equity | 0.8754 | N/A |
Earnings | 2023 | Change |
---|---|---|
Revenue | $16.17M | N/A |
Earnings | $10.56M | N/A |
EPS | 1.58 | N/A |
Earnings Yield | 0.0344 | N/A |
Gross Margin | 0.9354 | N/A |
Operating Margin | 0.7857 | N/A |
Net income margin | 0.6533 | N/A |
Financial Strength | 2023 | Change |
---|---|---|
Total Assets | $16.75M | N/A |
Cash on Hand | $7.21M | N/A |
Debt to Equity | 0.1274 | -7.94% |
Current Ratio | $10.08 | 6.87% |